X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/26/2904291/0/en/HUTCHMED-to-Announce-2024-Half-Year-Financial-Results.html
https://www.globenewswire.com/news-release/2024/06/24/2902801/0/en/Save-the-Date-HUTCHMED-to-Present-R-D-Updates-on-July-9-2024.html
https://www.globenewswire.com/news-release/2024/06/17/2899307/0/en/HUTCHMED-Highlights-Publication-of-Phase-III-ESLIM-01-Results-in-The-Lancet-Haematology.html
https://www.globenewswire.com/news-release/2024/06/07/2895128/0/en/HUTCHMED-Initiates-Phase-I-Trial-of-Menin-Inhibitor-HMPL-506-in-Patients-with-Hematological-Malignancies-in-China.html
https://www.globenewswire.com/news-release/2024/06/03/2891869/0/en/HUTCHMED-Highlights-Publication-of-Phase-III-FRUTIGA-Results-in-Nature-Medicine.html
https://www.globenewswire.com/news-release/2024/05/24/2887747/0/en/HUTCHMED-Highlights-Presentations-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/17/2884292/0/en/HUTCHMED-announces-retirement-of-Chairman-appointment-of-new-Chairman-and-change-of-members-of-board-committees.html
https://www.globenewswire.com/news-release/2024/05/17/2883983/0/en/HUTCHMED-Highlights-Sovleplenib-Phase-III-ESLIM-01-Study-and-Hematological-Malignancy-Programs-Data-to-be-Presented-at-the-upcoming-EHA2024-Congress.html
https://www.globenewswire.com/news-release/2024/05/14/2880988/0/en/HUTCHMED-Initiates-the-RAPHAEL-Registrational-Phase-III-Trial-of-HMPL-306-for-Patients-with-IDH1-and-or-IDH2-Mutated-Relapsed-Refractory-Acute-Myeloid-Leukemia-in-China.html
Market Place
Share 
